FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average bur	den									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Leal James (Last) (First) (Middle) C/O TANDEM DIABETES CARE, INC.			3. D	2. Issuer Name and Ticker or Trading Symbol TANDEM DIABETES CARE INC TNDM 3. Date of Earliest Transaction (Month/Day/Year) 08/29/2022										5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) SVP, Operations						
(Street) SAN DIF		Α !	92121 (Zip)		4. If															
(5.5)				n Davis		<u> </u>				Dia		of an D	£:		. 0					
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da			action	tion 2A. Deemed Execution Date,			quired, Disposed of, or Bene 3. Transaction Code (Instr. 8) 4. Securities Acquired (ADisposed Of (D) (Instr. 35)			red (A)	or 5. Amount o		nt of 6. Own		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
									Code	v	Amount	(A) (D)	Pri	Tronco		tion(s)			(,	
Common Stock 08/29/2					/2022	2022		М		309	309 A		\$ <mark>0</mark>	5,426			D			
Common Stock 08/29/2				/2022	2022		F ⁽¹⁾		138 D \$4		46.68	8 5,288			D					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	Date, Transact Code (Ins		on of		6. Date Exercisa Expiration Date (Month/Day/Year		r) Amount of Securities Underlyin		of s ng e Security		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisal		expiration Pate	Title	Amo or Num of Shar	ber						
Restricted Stock Unit ⁽²⁾	(3)	08/29/2022			M		309		(4)		(4)	Commor Stock	30	9	\$0	2,168		D		

Explanation of Responses:

- 1. Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
- 2. Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan (the "2013 Plan").
- 3. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.
- 4. RSUs granted on 5/27/2020 vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on the one year anniversary of the grant date, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter, subject to the terms of the 2013 Plan.

Remarks:

s/ Rachel Malina, Attorney-in-Fact for James A. Leal

08/31/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.